Charles River Laboratories International, Inc. $CRL Stake Trimmed by Cooke & Bieler LP

Cooke & Bieler LP reduced its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 42.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 432,121 shares of the medical research company’s stock after selling 323,509 shares during the quarter. Charles River Laboratories International comprises 1.9% of Cooke & Bieler LP’s investment portfolio, making the stock its 13th largest position. Cooke & Bieler LP’s holdings in Charles River Laboratories International were worth $127,480,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Physician Wealth Advisors Inc. increased its stake in shares of Charles River Laboratories International by 127.9% during the third quarter. Physician Wealth Advisors Inc. now owns 98 shares of the medical research company’s stock valued at $29,000 after buying an additional 55 shares during the period. Activest Wealth Management raised its holdings in shares of Charles River Laboratories International by 25.9% during the third quarter. Activest Wealth Management now owns 277 shares of the medical research company’s stock valued at $82,000 after acquiring an additional 57 shares in the last quarter. Empirical Finance LLC raised its holdings in shares of Charles River Laboratories International by 4.4% during the second quarter. Empirical Finance LLC now owns 1,469 shares of the medical research company’s stock valued at $333,000 after acquiring an additional 62 shares in the last quarter. Glenmede Trust Co. NA lifted its stake in Charles River Laboratories International by 2.8% in the first quarter. Glenmede Trust Co. NA now owns 2,706 shares of the medical research company’s stock worth $467,000 after acquiring an additional 73 shares during the period. Finally, Syon Capital LLC lifted its stake in Charles River Laboratories International by 2.4% in the second quarter. Syon Capital LLC now owns 3,547 shares of the medical research company’s stock worth $804,000 after acquiring an additional 83 shares during the period. 98.91% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently weighed in on CRL shares. CLSA cut shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price target on the stock. in a report on Monday, July 20th. Robert W. Baird boosted their price objective on shares of Charles River Laboratories International from $291.00 to $334.00 and gave the company an “outperform” rating in a research report on Friday, September 25th. Piper Sandler set a $300.00 target price on shares of Charles River Laboratories International in a research report on Monday, August 10th. TD Cowen lifted their target price on shares of Charles River Laboratories International from $300.00 to $325.00 and gave the company a “buy” rating in a research note on Friday, September 25th. Finally, UBS Group assumed coverage on shares of Charles River Laboratories International in a research note on Wednesday, September 30th. They set a “buy” rating and a $357.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $302.33.

Charles River Laboratories International Stock Up 9.3%

CRL stock opened at $344.80 on Thursday. Charles River Laboratories International, Inc. has a fifty-two week low of $146.20 and a fifty-two week high of $348.95. The company has a market capitalization of $16.46 billion, a price-to-earnings ratio of -71.09, a price-to-earnings-growth ratio of 2.95 and a beta of 1.40. The business’s 50 day moving average price is $291.87 and its two-hundred day moving average price is $231.25. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%. The firm’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same quarter last year, the business posted $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, analysts forecast that Charles River Laboratories International, Inc. will post 11.38 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Victoria Creamer sold 4,179 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the completion of the transaction, the executive vice president owned 30,051 shares of the company’s stock, valued at approximately $7,788,017.16. This trade represents a 12.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Nancy C. Andrews sold 573 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $285.24, for a total value of $163,442.52. Following the transaction, the director directly owned 1,438 shares of the company’s stock, valued at $410,175.12. This represents a 28.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 91,971 shares of company stock valued at $26,033,968 over the last 90 days. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.